4//SEC Filing
Dahan Michel 4
Accession 0001562180-24-004025
CIK 0001517022other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 4:04 PM ET
Size
5.2 KB
Accession
0001562180-24-004025
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2024-05-13$1.26/sh−34,840$43,898→ 672,092 total
Footnotes (2)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
- [F2]This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023.
Documents
Issuer
Akebia Therapeutics, Inc.
CIK 0001517022
Entity typeother
Related Parties
1- filerCIK 0001669737
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 4:04 PM ET
- Size
- 5.2 KB